The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Open accessAbstract
Objective: To evaluate patterns of antipsychotic use. Design, setting, and measurements: We used nationally representative data from the IMS Health National Disease and Therapeutic Index to describe outpatient antipsychotic use. The primary outcome was the volume of visits where antipsychotics were used for specific indications (treatment visits). We also quantified use without U.S. Food and Drug Administration approval (off‐label use) and off‐label use with compendium data suggesting an uncertain evidence base. Results: Antipsychotic use increased from 6.2 million (M) treatment visits (95% CI, 5.4–7.0) in 1995 to 16.7 M visits (15.5–18.2) in 2006, then declined to 14.3 M visits (13.0–15.6) by 2008. A shift occurred from typical agents in 1995 (84% of all antipsychotic visits) to atypical agents by 2008 (93%). As they declined, typical medications shifted toward use in schizophrenia (30% in 1995 to 48% 2008). In contrast, use of atypical agents expanded for bipolar affective disorder (10 to 34%), remained stable for depression (12 to 14%), and declined for schizophrenia (56 to 23%). Overall, antipsychotic use for indications without FDA approval increased from 4.4 M visits in 1995 to 9.0 M in 2008. The estimated cost associated with off‐label use in 2008 was US$6.0 billion. Conclusions: Atypical use has grown far beyond substitution for the now infrequently used typical agents. Antipsychotics are increasingly used for conditions where FDA approval and associated clinical evidence is less certain. Despite the value of innovation, the benefits of widening atypical antipsychotic use should be weighed against their cost, regulatory status, and incomplete nature of available evidence. Copyright © 2011 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yatham, L., & Malhi, G. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,506
Atypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
National Trends in the Outpatient Diagnosis and Treatment of Bipolar Disorder in Youth
Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A. B., & Olfson, M. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1032 · Cited by 724
Antipsychotic Drug Use and Mortality in Older Adults with Dementia
Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-11-200706050-00006 · Cited by 624
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 478
The underutilization of cardiacmedications of proven benefit, 1990 to 2002
Stafford, R. S., & Radley, D. C. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02670-0 · Cited by 286
Self-citationSmith, M., Hopkins, D., Peveler, R. C., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 275
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq042 · Cited by 272
Crystal, S., Olfson, M., Huang, C., Pincus, H., & Gerhard, T. (2009) · Health Affairs · doi:10.1377/hlthaff.28.5.w770 · Cited by 268
Cited by
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Alexander, G. C., Tajanlangit, M., Heyward, J., Mansour, O., Qato, D. M., & Stafford, R. S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.21476 · Cited by 468
Self-citationOlfson, M., Blanco, C., Wang, S., Laje, G., & Correll, C. U. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3074 · Cited by 449
A systematic review and meta-analysis of premature mortality in bipolar affective disorder
Hayes, J. F., Miles, J., Walters, K., King, M., & Osborn, D. P. J. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12408 · Cited by 370
Ten common questions (and their answers) about off-label drug use
Wittich, C. M., Burkle, C. M., & Lanier, W. L. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.04.017 · Cited by 368
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Olfson, M., Blanco, C., Liu, S.-M., Wang, S., & Correll, C. U. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.647 · Cited by 352
International trends in antipsychotic use: A study in 16 countries, 2005–2014
Hálfdánarson, Ó., Zoëga, H., Aagaard, L., Bernardo, M., Brandt, L., Fusté, A. C., Furu, K., Garuoliené, K., Hoffmann, F., Huybrechts, K. F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.001 · Cited by 282
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010
Ilyas, S., & Moncrieff, J. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.104257 · Cited by 260
Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011
Stephenson, C. P., Karanges, E., & McGregor, I. S. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412466595 · Cited by 217
Nillni, Y. I., Mehralizade, A., Mayer, L., & Milanovic, S. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.004 · Cited by 207
Psychotropic medicine consumption in 65 countries and regions, 2008-19: A longitudinal study
Brauer, R., Alfageh, B., Blais, J. E., Chan, E. W., Chui, C. S. L., Hayes, J. F., Man, K. K. C., Lau, W. C. Y., Yan, V. K. C., Beykloo, M. Y., et al. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00292-3 · Cited by 203
Pharmacological Treatment of Insomnia.
(2015) · PubMed Central · Cited by 109
Correll, C. U., Joffe, B. I., Rosen, L. M., Sullivan, T. B., & Joffe, R. T. (2015) · World Psychiatry · doi:10.1002/wps.20187 · Cited by 102
Antipsychotic prescribing patterns during and after critical illness: A prospective cohort study.
Tomichek, J. E., Stollings, J. L., Pandharipande, P. P., Chandrasekhar, R., Ely, E. W., & Girard, T. D. (2016) · Critical Care · doi:10.1186/s13054-016-1557-1 · Cited by 100
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Treatment-emergent adverse events associated with atypical antipsychotics
Cha, D. S., & McIntyre, R. S. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656590 · Cited by 68
Zivkovic, S., Koh, C. H., Kaza, N., & Jackson, C. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2177-5 · Cited by 65
Hsu, W.-T., Esmaily-Fard, A., Lai, C.-C., Zala, D., Lee, S.-H., Chang, S.-S., & Lee, C.-C. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.02.020 · Cited by 59
Milstein, J. A., Elnabawi, A., Vinish, M., Swanson, T., Enos, J. K., Bailey, A. M., Kolb, B., & Frost, D. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057308 · Cited by 57
Albert, U., Carmassi, C., Cosci, F., De Cori, D., Di Nicola, M., Ferrari, S., Poloni, N., Tarricone, I., & Fiorillo, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000127 · Cited by 58
Pillarella, J., Higashi, A., Alexander, G. C., & Conti, R. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201100092 · Cited by 53
Self-citationRizvi, S. J., Salomons, T. V., Konarski, J. Z., Downar, J., Giacobbe, P., McIntyre, R. S., & Kennedy, S. H. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.050 · Cited by 45
Moncrieff, J., Gupta, S., & Horowitz, M. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320937910 · Cited by 43
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2016) · Focus · doi:10.1176/appi.focus.140202 · Cited by 20
Hulvershorn, L., Parkhurst, S., Jones, S., Dauss, K., & Adams, C. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0040 · Cited by 6
Metadata
- Authors
- Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2011-01-06
- Volume
- 20
- Issue
- 2
- Pages
- 177-184
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2164142166
- Cited by
- 423
- References
- 17
- FWCI
- 26.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.